Burney Co. Makes New $1.37 Million Investment in Novo Nordisk A/S $NVO

Key Points

• Burney Co. filed a new 13F stake in Novo Nordisk, buying 27,010 shares worth about $1.37 million during the fourth quarter.
• Novo Nordisk has several near‑term catalysts including a strategic partnership with OpenAI to speed drug discovery, a DKK 15 billion share repurchase programme, and nationwide U.S. availability of higher‑dose Wegovy HD.
• Analysts' consensus is a Hold (average target $65.56) while the stock traded around $37.97 with a 12‑month range of $35.12–$81.44, reflecting recent volatility and mixed sentiment.

Burney Co. acquired a new stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 27,010 shares of the company's stock, valued at approximately $1,374,000.

A number of other hedge funds have also made changes to their positions in the stock. Martin Capital Partners LLC lifted its position in shares of Novo Nordisk A/S by 53.8% during the 3rd quarter. Martin Capital Partners LLC now owns 117,577 shares of the company's stock worth $6,524,000 after buying an additional 41,129 shares during the period. Smith Chas P & Associates PA Cpas lifted its position in shares of Novo Nordisk A/S by 105.3% during the 3rd quarter. Smith Chas P & Associates PA Cpas now owns 405,425 shares of the company's stock worth $22,497,000 after buying an additional 207,959 shares during the period. Clifford Swan Investment Counsel LLC lifted its position in shares of Novo Nordisk A/S by 13.7% during the 3rd quarter. Clifford Swan Investment Counsel LLC now owns 311,168 shares of the company's stock worth $17,267,000 after buying an additional 37,453 shares during the period. Markel Group Inc. lifted its position in shares of Novo Nordisk A/S by 4.9% during the 3rd quarter. Markel Group Inc. now owns 2,368,649 shares of the company's stock worth $131,436,000 after buying an additional 110,061 shares during the period. Finally, Cantor Fitzgerald Investment Advisors L.P. bought a new position in shares of Novo Nordisk A/S during the 3rd quarter worth approximately $1,294,000. Institutional investors and hedge funds own 11.54% of the company's stock.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk announced a strategic partnership with OpenAI to integrate advanced AI across drug discovery, manufacturing and commercial operations — management says AI will speed candidate identification and data analysis, which could cut development time and costs and boost long‑term R&D productivity. Reuters: Wegovy-maker Novo Nordisk partners with OpenAI to speed drug development
• Positive Sentiment: Major media coverage (WSJ, CNBC) amplifies the OpenAI tie‑up, improving sentiment among growth and tech‑oriented investors who see AI partnerships as a catalyst for faster pipeline readouts and operational gains. CNBC: Novo Nordisk partners with OpenAI as AI drug discovery hopes mount
• Positive Sentiment: Company-initiated share repurchase programme (part of a DKK 15B plan) signals capital return priority and provides support to the share price by reducing float and showing board confidence in valuation. GlobeNewswire: Novo Nordisk A/S - share repurchase programme
• Positive Sentiment: Product update: Wegovy HD (7.2 mg) is now available nationwide in the U.S., supporting commercial recovery and higher‑dose pricing potential versus earlier formulations. This is a near‑term commercial positive if uptake and reimbursement follow. Yahoo Finance: How Novo Nordisk (NVO) Is Expanding Its Dominance in Obesity Care
• Positive Sentiment: Bullish analyst/opinion pieces argue the pullback is a buying opportunity — citing 2025 cash flow, dividend yield and pipeline depth — which can attract income and value investors seeking exposure to the obesity/diabetes market longer term. Seeking Alpha: Novo Nordisk: Don't Stop Purchasing The Dip
• Neutral Sentiment: Coverage on niche markets (e.g., alpha thalassemia) highlights additional long‑term pipeline opportunities but these are unlikely to move the stock near term. Yahoo/ResearchAndMarkets: Alpha Thalassemia Market Insights
• Neutral Sentiment: FT feature examines Novo Nordisk’s strategy to regain momentum in weight‑loss drugs — narrative helps framing but is more qualitative than a direct catalyst. Financial Times: Weight-loss drugs and Mars bars: Novo Nordisk’s comeback bid
• Negative Sentiment: Bearish/concern pieces note a ~36% decline over three months driven by a weak 2026 outlook, intensifying GLP‑1 competition (notably from Eli Lilly) and pricing pressure — these factors keep near‑term revenue and margin risk elevated. Zacks: NVO Crashes 36% in 3 Months

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on NVO shares. Citigroup started coverage on Novo Nordisk A/S in a report on Tuesday, January 27th. They set a "neutral" rating for the company. Nordea Equity Research cut Novo Nordisk A/S to a "hold" rating in a report on Tuesday, February 24th. Kepler Capital Markets cut Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Tuesday, February 24th. Deutsche Bank Aktiengesellschaft cut Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Monday, February 23rd. Finally, Jefferies Financial Group raised Novo Nordisk A/S from an "underperform" rating to a "hold" rating in a report on Thursday, February 12th. Four equities research analysts have rated the stock with a Buy rating and twenty have given a Hold rating to the company. According to data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of "Hold" and an average target price of $65.56.

Novo Nordisk A/S Stock Up 1.2%

NYSE:NVO opened at $37.97 on Tuesday. The stock's fifty day simple moving average is $40.61 and its 200-day simple moving average is $48.79. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61. The firm has a market capitalization of $169.53 billion, a P/E ratio of 10.94, a P/E/G ratio of 8.85 and a beta of 0.73. Novo Nordisk A/S has a 12-month low of $35.12 and a 12-month high of $81.44.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, topping the consensus estimate of $0.90 by $0.11. The firm had revenue of $12.43 billion for the quarter, compared to analyst estimates of $11.97 billion. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%. Equities research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Dividend Announcement

The business also recently announced a dividend, which was paid on Wednesday, April 8th. Investors of record on Monday, March 30th were given a $1.2751 dividend. The ex-dividend date of this dividend was Monday, March 30th. This represents a dividend yield of 723.0%. Novo Nordisk A/S's payout ratio is currently 50.43%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.